Last reviewed · How we verify
Tardyferon
Tardyferon, marketed by Luzerner Kantonsspital, is a drug with a key composition patent expiring in 2028. The primary strength of Tardyferon lies in its current market presence, leveraging its established position. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Tardyferon |
|---|---|
| Sponsor | Luzerner Kantonsspital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimizing Dosing Strategies in Oral Iron Supplementation (PHASE4)
- The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females (NA)
- Cross Iron (Comparative Randomized Oral Versus Systemic IRON) (NA)
- Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia (PHASE1)
- Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tardyferon CI brief — competitive landscape report
- Tardyferon updates RSS · CI watch RSS
- Luzerner Kantonsspital portfolio CI